What Mid Cap Funds Bought and Sold in September 2026

    Blacklitt Research5 min read

    ₹7,164 crore net buying. Mid cap mutual funds, holdings as of 30 September 2026

    Mid cap mutual funds were net buyers of an estimated ₹7,164 crore in September 2026. Gland Pharma was the largest estimated buy, at ₹1,310 crore, and 25 of the 34 funds compared were net buyers. Holdings are as of 30 September 2026, compared with 31 August 2026.

    Biggest buys by mid cap funds

    Gland Pharma drew the largest estimated buying, with three funds adding to it and two taking new positions. All five of the largest buys were added by at least three funds each. Dixon Technologies (India) was held by 26 funds at both month-ends, with six funds adding and four cutting.

    StockSectorEstimated buying (₹ crore)Funds addingFunds holding at month-end
    Gland PharmaPharmaceuticals & Biotechnology131039
    Avalon TechnologiesElectrical Equipment57834
    Aditya InfotechIndustrial Manufacturing469710
    Max Healthcare InstituteHealthcare Services423714
    Dixon Technologies (India)Consumer Durables406626

    Data as of 30 September 2026, compared with 31 August 2026. Values are estimates: change in shares × month-end price.

    Largest buys by mid cap funds in September 2026
    ₹0₹500 crore₹1,000 crore₹1,500 croreGland PharmaGland Pharma · Estimated buying: ₹1,310 crore₹1,310 croreAvalon TechnologiesAvalon Technologies · Estimated buying: ₹578 crore₹578 croreAditya InfotechAditya Infotech · Estimated buying: ₹469 crore₹469 croreMax Healthcare InstituteMax Healthcare Institute · Estimated buying: ₹423 crore₹423 croreDixon Technologies (India)Dixon Technologies (India) · Estimated buying: ₹406 crore₹406 crore

    Estimates. Data as of 30 September 2026.

    Aditya Infotech had seven funds adding and four new positions, while two funds sold out of it completely. For one fund's mid cap holdings in the same month, see the HDFC Mid Cap Fund holdings for September 2026.

    Biggest sells by mid cap funds

    Five stocks drew the largest estimated selling. BSE stood out, with ten funds cutting it and four selling out completely. Power Finance Corporation was held by one fund at the end of September, against three at the end of August.

    StockSectorEstimated selling (₹ crore)Funds cuttingFull exits
    BSECapital Markets423104
    Power Finance CorporationFinance37822
    Shriram FinanceFinance33652
    One97 CommunicationsFinancial Technology (Fintech)31350
    JSW EnergyPower25520

    Data as of 30 September 2026, compared with 31 August 2026. Values are estimates: change in shares × month-end price.

    Shriram Finance was held by eight funds at the end of September, against 10 a month earlier. One97 Communications had five funds adding and five cutting, and an estimated ₹313 crore sold on net.

    Sector flows and newly held stocks

    Pharmaceuticals & Biotechnology had the largest estimated net buying among sectors, at ₹1,860 crore. Finance had the largest estimated net selling, at ₹496 crore.

    SectorNet directionEstimated value (₹ crore)
    Pharmaceuticals & BiotechnologyNet buying1860
    RetailingNet buying1319
    Healthcare ServicesNet buying888
    FinanceNet selling496
    Industrial ProductsNet selling346
    Financial Technology (Fintech)Net selling310

    Data as of 30 September 2026, compared with 31 August 2026. Values are estimates: change in shares × month-end price, summed by sector.

    Five stocks were newly held by mid cap funds this month. National Stock Exchange Of India was held by four funds, valued at an estimated ₹62 crore, and SS Retail by two funds, at an estimated ₹81 crore. The Federal Bank was the most widely held stock, with 28 funds holding it.

    Reading monthly holdings data

    Holdings are disclosed monthly, so each figure compares two month-end snapshots. Values are estimates: the change in shares held, multiplied by the month-end price, since funds do not disclose the prices they paid or received. A monthly snapshot misses trades made and reversed within the month, so a stock can look unchanged while it was traded in between. A fund buying a stock is one manager's decision, sized for that portfolio, and one fund's purchase is not advice. New to the category? Read what a mid cap fund is first.

    Frequently asked questions

    Which stocks did mid cap funds buy in September 2026?

    Gland Pharma led with an estimated ₹1,310 crore, followed by Avalon Technologies (₹578 crore), Aditya Infotech (₹469 crore), Max Healthcare Institute (₹423 crore) and Dixon Technologies (India) (₹406 crore). These are estimates from the change in shares held, multiplied by month-end prices, for holdings as of 30 September 2026. Three funds added to Gland Pharma and two took new positions.

    Which stocks did mid cap funds sell in September 2026?

    BSE topped the sell list with an estimated ₹423 crore sold, followed by Power Finance Corporation (₹378 crore), Shriram Finance (₹336 crore), One97 Communications (₹313 crore) and JSW Energy (₹255 crore). Ten funds cut their BSE holding, and four sold out of it completely. Values are estimates from month-end prices, not the prices funds received.

    Where can I see a mutual fund's holdings?

    Fund houses publish monthly portfolios on their websites within 10 days of month-end, as SEBI requires. The figures in this article compare disclosures for 30 September 2026 with 31 August 2026. Rupee values here are estimates, so the fund's own disclosure is the place to check exact share counts.

    Are mid cap fund purchases a recommendation?

    No. A fund buying a stock is one manager's decision, sized for that portfolio. The data shows what changed in holdings between two month-ends, and nothing about the stock's outlook. Holdings are disclosed monthly, so a snapshot cannot show trades made and reversed within the month. Use the figures to see what funds did, one month at a time.

    Disclaimer

    Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

    The funds on this page are shown for information and education, with figures as of 30 September 2026. Past performance does not indicate future returns. This is not personalised investment advice or a recommendation to buy or sell any fund, so check that a fund suits your own goals, time horizon and risk appetite, or speak to an adviser, before you invest.

    Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

    Blacklitt Technologies Private Limited · SEBI RIA INA000022428 · BSE enlistment 2491

    Keep reading